Healthcare · Biotechnology
Price
$1.14
Market Cap
$305.8M
Employees
181
Beta
0.25
Avg Volume
4,391,801
CEO
John Butler
Business Description
Akebia Therapeutics, Inc., established in 2007 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and commercializing therapies for patients suffering from kidney diseases. The firm's leading experimental drug, vadadustat, is an oral treatment currently in Phase III clinical trials. Its purpose is to address anemia resulting from chronic kidney disease (CKD) in adult patients, encompassing both those dependent on dialysis and those who are not. Akebia also markets Auryxia, a ferric citrate product used to manage serum phosphorus levels in adult CKD patients undergoing dialysis, and to treat iron deficiency anemia in adult CKD patients who are not on dialysis. The company has several key collaboration agreements: with Otsuka Pharmaceutical Co. Ltd. for vadadustat's development and commercialization across major regions including the United States, European Union, Russia, China, Australia, Canada, and the Middle East; with Mitsubishi Tanabe Pharma Corporation for vadadustat in Japan and other Asian territories; and a research and licensing deal with Janssen Pharmaceutica NV pertaining to hypoxia-inducible factor prolyl hydroxylase targeted compounds globally.
Business History
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-54.81
Stock Price: $1.14
EPS (Diluted): -0.02
EPS (Diluted): -0.02
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
12.70
Stock Price: $1.14
Total Equity: $32.61M
Shares: 257,157,782
Total Equity: $32.61M
Shares: 257,157,782
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
20.50
Market Cap: $305.81M
Total Debt: $216.30M
Cash: $184.84M
EBITDA: $21.73M
Total Debt: $216.30M
Cash: $184.84M
EBITDA: $21.73M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$445.5M
Market Cap: $305.81M
Total Debt: $216.30M
Cash: $184.84M
Total Debt: $216.30M
Cash: $184.84M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
1.75
Stock Price: $1.14
Revenue: $236.20M
Shares: 257,157,782
Revenue: $236.20M
Shares: 257,157,782
EV/Sales (Total value vs revenue — works when P/E can't)
API1.89
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
83.3%
Gross Profit: $196.73M
Revenue: $236.20M
Revenue: $236.20M
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
9.9%
Operating Income: $23.50M
Revenue: $236.20M
Revenue: $236.20M
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
-2.3%
Net Income: -$5.35M
Revenue: $236.20M
Revenue: $236.20M
ROE (Profit from shareholder equity)
CALCNet Income / Total Equity
-16.4%
Net Income: -$5.35M
Total Equity: $32.61M
Total Equity: $32.61M
ROIC (Profit from all invested capital)
CALCNOPAT / Invested Capital
52.7%
Operating Income: $23.50M
Tax Rate: -43.6%
Equity: $32.61M
Total Debt: $216.30M
Cash: $184.84M
Tax Rate: -43.6%
Equity: $32.61M
Total Debt: $216.30M
Cash: $184.84M
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
1.13
Current Assets: $184.84M
Current Liabilities: $162.94M
Current Liabilities: $162.94M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
6.63
Short-Term Debt: $40.08M
Long-Term Debt: $176.21M
Total Debt: $216.30M
Total Equity: $32.61M
Long-Term Debt: $176.21M
Total Debt: $216.30M
Total Equity: $32.61M
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$0.92
Revenue: $236.20M
Shares: 257,157,782
Shares: 257,157,782
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$0.13
Total Equity: $32.61M
Shares: 257,157,782
Shares: 257,157,782
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$0.26
Operating CF: $67.99M
CapEx: -$291,000
Shares: 257,157,782
CapEx: -$291,000
Shares: 257,157,782
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $1.14
Stock Price: $1.14
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$5.35M
Net Income: -$5.35M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares AKBA against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 23, 2026 4:01am (4d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $211.7M | $292.5M | $194.6M | $160.2M | $236.2M |
| Cost of Revenue | $81.5M | $22.5M | $74.1M | $63.2M | $39.5M |
| Gross Profit | $130.2M | $270.0M | $120.5M | $97.0M | $196.7M |
| Operating Expenses | $394.7M | $350.8M | $166.7M | $147.5M | $173.2M |
| Operating Income | -$264.5M | -$80.8M | -$46.3M | -$50.5M | $23.5M |
| Net Income | -$282.0M | -$94.2M | -$51.9M | -$69.4M | -$5.3M |
| EBITDA | -$189.9M | $3.1M | -$8.3M | -$13.7M | $21.7M |
| EPS | $-1.48 | $-0.58 | $-0.28 | $-0.33 | $-0.02 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 23, 2026 4:01am (4d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $149.8M | $90.5M | $42.9M | $51.9M | $184.8M |
| Total Current Assets | $271.1M | $185.2M | $118.1M | $113.8M | $184.8M |
| Total Assets | $529.3M | $356.1M | $241.7M | $220.7M | $376.6M |
| Current Liabilities | $261.1M | $129.5M | $99.9M | $80.9M | $162.9M |
| Long-Term Debt | $53.1M | $34.1M | $71.2M | $175.5M | $176.2M |
| Total Liabilities | $455.3M | $350.8M | $272.3M | $269.9M | $344.0M |
| Total Equity | $74.0M | $5.2M | -$30.6M | -$49.2M | $32.6M |
| Retained Earnings | -$1.5B | -$1.6B | -$1.6B | -$1.7B | -$1.7B |
Cash Flow (Annual)
Last updated: Jun 23, 2026 4:01am (4d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$253.0M | -$73.2M | -$23.4M | -$40.7M | $68.0M |
| Capital Expenditure | $-59,000 | $-114,000 | $0 | $-33,000 | $-291,000 |
| Free Cash Flow | -$253.0M | -$73.3M | -$23.4M | -$40.7M | $68.0M |
| Acquisitions (net) | $0 | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | -$1.3M | $0 |
| Net Change in Cash | -$79.3M | -$58.7M | -$48.6M | $9.0M | $133.0M |
Analyst Estimates (Annual)
Last updated: Jun 26, 2026 5:11pm (15h ago)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$159.7M $158.3M – $161.1M
|
$202.4M $185.7M – $212.6M
|
$221.5M $203.2M – $232.6M
|
$263.0M $241.4M – $276.3M
|
| EBITDA |
-$29.5M -$29.7M – -$29.2M
|
-$37.4M -$39.2M – -$34.3M
|
-$40.9M -$42.9M – -$37.5M
|
-$48.6M -$51.0M – -$44.6M
|
| Net Income |
-$60.2M -$63.3M – -$57.0M
|
-$27.8M -$50.1M – $4.8M
|
-$12.9M -$13.7M – -$11.5M
|
$1.7M $1.5M – $1.8M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 23, 2026 4:01am (4d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +38.2% | -33.5% | -17.7% | +47.5% |
| Gross Profit Growth | +107.4% | -55.4% | -19.5% | +102.8% |
| Operating Income Growth | +69.5% | +42.7% | -9.1% | +146.6% |
| Net Income Growth | +66.6% | +44.9% | -33.7% | +92.3% |
| EBITDA Growth | +101.6% | -370.5% | -66.0% | +258.3% |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for AKBA — it's generated by the pipeline (
market-narrative step).
No community reviews yet for AKBA.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30